Atosiban
Hormonal / ClinicalAlso known as: Tractocile
Mechanism
A drug that blocks oxytocin receptors to stop premature uterine contractions in preterm labor. Unlike older preterm labor drugs (like beta-agonists) that cause heart racing and tremors, atosiban has very few side effects. Approved in Europe but not in the US, where it failed to show superiority over placebo in FDA trials — a controversial regulatory outcome.
Technical detail
Synthetic nonapeptide competitive antagonist of both oxytocin receptor (OTR) and vasopressin V1a receptor. Structure: 1-deamino-[D-Tyr(Et)2, Thr4, Orn8]-oxytocin. Blocks OTR-mediated Gq/PLC/IP3/Ca2+ signaling in myometrial cells, inhibiting uterine contractions. Also antagonizes V1a-mediated prostaglandin release from decidua. Administration: IV bolus (6.75 mg) + infusion (18 mg/hr for 3 hours, then 6 mg/hr for up to 45 hours). Half-life ~13 min (rapid offset advantageous for fetal safety). Placenta transfer minimal. Meta-analyses show comparable tocolytic efficacy to nifedipine and beta-agonists but superior maternal tolerability (significantly fewer cardiovascular and metabolic side effects). US Phase III trials (2001) did not meet primary endpoint, preventing FDA approval.
Effects
**Reproductive System — Uterine (Tier 1 — Human Clinical):** Atosiban is a competitive antagonist at oxytocin receptors (OTR) and vasopressin V1a receptors on uterine myometrial cells. It inhibits oxytocin-mediated intracellular calcium release, reducing myometrial contractility. In clinical trials, atosiban significantly reduced uterine contraction frequency and intensity in women with preterm labor (24–33 weeks gestation), delaying delivery by 48 hours to 7 days compared to placebo. **Reproductive System — IVF (Tier 2 — Human Clinical):** Emerging evidence suggests atosiban improves IVF implantation rates when administered during embryo transfer. By reducing uterine contractions during and after transfer, it may prevent embryo expulsion. Several RCTs show improved pregnancy rates, particularly in patients with recurrent implantation failure. **Cardiovascular (Tier 1 — Human Clinical, Safety Profile):** Unlike beta-agonist tocolytics (ritodrine, terbutaline), atosiban has minimal cardiovascular side effects. No significant maternal tachycardia, hypotension, or cardiac arrhythmias. This is a major advantage over older tocolytic agents. **Metabolic (Tier 1 — Human Clinical, Safety Profile):** No effect on maternal glucose metabolism, unlike beta-agonists. Safe in diabetic mothers. No fetal metabolic effects documented.
Practitioner Guide
**APPROVED INDICATION:** • Tocolysis (inhibition of preterm labor) in women with preterm contractions between 24–33 weeks gestation. Approved in Europe (Tractocile); NOT approved by FDA in the United States. **DOSING PROTOCOL (European Approval):** • Step 1 — IV bolus: 6.75 mg over 1 minute. • Step 2 — High-dose infusion: 18 mg/hour IV for 3 hours. • Step 3 — Maintenance infusion: 6 mg/hour IV for up to 45 hours. • Maximum treatment duration: 48 hours per course. May be retreated if contractions recur. **IVF EMBRYO TRANSFER PROTOCOL (Off-Label):** • IV bolus: 6.75 mg over 1 minute, administered 30 minutes before embryo transfer. • Followed by IV infusion: 6 mg/hour for 2–4 hours post-transfer. • Alternative simplified protocol: Single IV bolus of 6.75 mg at time of embryo transfer. Some clinics use this shorter protocol with reported success. **CLINICAL PEARLS:** • Atosiban is preferred over beta-agonists in Europe for tocolysis due to its superior maternal safety profile (fewer cardiac and metabolic side effects). • In the US, nifedipine and indomethacin remain first-line tocolytics since atosiban is not FDA-approved. FDA declined approval citing non-superiority to placebo in one trial, though methodology was disputed. • For IVF: Growing evidence supports use in recurrent implantation failure cases. Not yet standard of care but increasingly adopted in reproductive medicine centers, particularly in Europe and Asia. • Contraindications: Do not use before 24 weeks or after 33 weeks gestation. Not indicated for preterm premature rupture of membranes (PPROM) as a standalone treatment.
Research Summary
**Tier 1 (Human Clinical Evidence):** • Pivotal trials: Multiple Phase III RCTs demonstrate atosiban delays preterm delivery by ≥48 hours (sufficient for antenatal corticosteroid administration). The 48-hour delay is the primary clinical goal — allowing steroid-mediated fetal lung maturation. • Safety: Superior maternal safety profile vs beta-agonists and calcium channel blockers. Fewer treatment discontinuations due to side effects. • IVF: Several RCTs and meta-analyses show improved implantation and clinical pregnancy rates in IVF patients receiving atosiban during embryo transfer, with the strongest signal in recurrent implantation failure populations. **Tier 2 (Strong Preclinical + Mechanistic):** • Oxytocin receptor pharmacology is well-characterized. Atosiban is a mixed OTR/V1a antagonist, which may contribute to its efficacy since both receptors drive uterine contractility. • The IVF mechanism (reducing uterine contractions during implantation window) is physiologically sound — ultrasound studies confirm reduced junctional zone activity with atosiban. **Tier 3 (Emerging / Theoretical):** • Potential neuroprotective effects in fetal brain during preterm labor (via OTR modulation in developing CNS) — preliminary animal data. • Investigation as adjunct in other assisted reproduction scenarios (surrogacy, frozen embryo transfer) is ongoing.